1. Home
  2. APGE vs BATRK Comparison

APGE vs BATRK Comparison

Compare APGE & BATRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APGE
  • BATRK
  • Stock Information
  • Founded
  • APGE 2022
  • BATRK 1991
  • Country
  • APGE United States
  • BATRK United States
  • Employees
  • APGE N/A
  • BATRK N/A
  • Industry
  • APGE Biotechnology: Biological Products (No Diagnostic Substances)
  • BATRK Broadcasting
  • Sector
  • APGE Health Care
  • BATRK Industrials
  • Exchange
  • APGE Nasdaq
  • BATRK Nasdaq
  • Market Cap
  • APGE 2.4B
  • BATRK 2.5B
  • IPO Year
  • APGE 2023
  • BATRK N/A
  • Fundamental
  • Price
  • APGE $55.35
  • BATRK $39.91
  • Analyst Decision
  • APGE Strong Buy
  • BATRK Strong Buy
  • Analyst Count
  • APGE 8
  • BATRK 3
  • Target Price
  • APGE $94.63
  • BATRK $58.00
  • AVG Volume (30 Days)
  • APGE 923.1K
  • BATRK 280.2K
  • Earning Date
  • APGE 11-12-2025
  • BATRK 11-05-2025
  • Dividend Yield
  • APGE N/A
  • BATRK N/A
  • EPS Growth
  • APGE N/A
  • BATRK N/A
  • EPS
  • APGE N/A
  • BATRK N/A
  • Revenue
  • APGE N/A
  • BATRK $702,443,000.00
  • Revenue This Year
  • APGE N/A
  • BATRK $14.16
  • Revenue Next Year
  • APGE N/A
  • BATRK $3.97
  • P/E Ratio
  • APGE N/A
  • BATRK N/A
  • Revenue Growth
  • APGE N/A
  • BATRK 6.51
  • 52 Week Low
  • APGE $26.20
  • BATRK $35.46
  • 52 Week High
  • APGE $63.50
  • BATRK $47.18
  • Technical
  • Relative Strength Index (RSI)
  • APGE 66.05
  • BATRK 43.76
  • Support Level
  • APGE $54.80
  • BATRK $38.46
  • Resistance Level
  • APGE $57.23
  • BATRK $40.19
  • Average True Range (ATR)
  • APGE 2.61
  • BATRK 0.75
  • MACD
  • APGE -0.18
  • BATRK 0.13
  • Stochastic Oscillator
  • APGE 62.75
  • BATRK 64.80

About APGE Apogee Therapeutics Inc.

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

About BATRK Atlanta Braves Holdings Inc. Series C

Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.

Share on Social Networks: